Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous AMSCs for Preventing Biliary Complications After Living Donor Liver Transplant
NCT06649864Phase 1Not yet recruiting
- Sponsor
- Mayo Clinic
- Start
- Feb 2027
- Primary completion
- Jan 2028
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of autologous adipose-derived mesenchymal stromal cells, sponsored by Mayo Clinic. Primary endpoint: Incidence of side effects at 24 months. Planned start Feb 2027; status: not yet recruiting.
02
Drugs
autologous adipose-derived mesenchymal stromal cells
Beyond the preview
Go deeper on NCT06649864.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06649864.